GlaxoSmithKline PLC (GSK) - Stock Price & Dividends

Exchange: London Exchange • Country: United Kingdom • Currency: GBX • Type: Common Stock • ISIN: GB00BN7SWP63

GSK plc, with various subsidiaries, focuses on researching, developing, and producing vaccines and specialty medicines to prevent and treat diseases worldwide, including in the UK and the US. The company segments into Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Its product line includes medicines addressing infectious diseases, HIV, immunology, respiratory issues, and oncology. Originally known as GlaxoSmithKline plc, the company rebranded to GSK plc as of May 2022. Established in 1715, GSK plc is headquartered in Brentford, UK. More information can be found at https://www.gsk.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for GlaxoSmithKline PLC (GSK) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for GlaxoSmithKline PLC (GSK) - Stock Price & Dividends

GSK Stock Overview

Market Cap in USD 876m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception

GSK Stock Ratings

Fundamental 3.97
Dividend 4.46
Growth 5y 3.07
Rel. Performance vs Sector 0.48
Analysts -
Fair Price Momentum 1634.65 GBX
Fair Price DCF 28.36 GBX

GSK Dividends

Yield 12m 3.39%
Yield on Cost 5y 4.58%
Dividends CAGR 5y -6.97%
Payout Consistency 95.2%

GSK Growth Ratios

Growth 12m 24.42%
Growth Correlation 12m 53%
Growth Correlation 3m 72%
CAGR 5y 6.16%
Sharpe Ratio 12m 1.07
Alpha vs SP500 12m 11.69
Beta vs SP500 5y weekly 0.29
ValueRay RSI 75.52
Volatility GJR Garch 1y 18.45%
Price / SMA 50 4.24%
Price / SMA 200 16.81%
Current Volume 6643k
Average Volume 20d 8257.7k

External Links for GSK Stock

Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of GSK stocks?
As of March 29, 2024, the stock is trading at GBX 1708.60 with a total of 6,642,999 shares traded.
Over the past week, the price has changed by +2.08%, over one month by +2.32%, over three months by +18.07% and over the past year by +25.12%.
What is the forecast for GSK stock price target?
According to ValueRays Forecast Model, GSK GlaxoSmithKline PLC will be worth about 1775.2 in March 2025. The stock is currently trading at 1708.60. This means that the stock has a potential upside of +3.9%.
Issuer Forecast Upside
Wallstreet Target Price 2128.3 24.6%
Analysts Target Price - -
ValueRay Target Price 1775.2 3.90%

Exploring GlaxoSmithKline PLC: A Journey Through Time

History

GlaxoSmithKline PLC, widely known as GSK, has a rich history that spans over a century. The company's origins trace back to London in 1715, evolving through multiple mergers and acquisitions. A significant merger in 2000 between Glaxo Wellcome and SmithKline Beecham marked the birth of GSK as we know it today. This merger combined vast portfolios of medications, vaccines, and consumer healthcare products, making GSK one of the pharmaceutical industry's giants.

Core Business

GSK primarily focuses on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. In Pharmaceuticals, GSK stands out for its innovative treatments in areas such as respiratory diseases, HIV/AIDS, and oncology. The Vaccines division is renowned for its broad range of pediatric, adolescent, and adult vaccines, each designed to prevent infectious diseases worldwide. Additionally, GSK's Consumer Healthcare division offers well-known over-the-counter (OTC) products, including oral health and nutritional products, underscoring its versatility and impact on everyday health.

Side Businesses and Collaborations

Beyond its core operations, GSK actively engages in research collaborations and partnerships to fuel innovation. This includes working with biotech firms, academic institutions, and other pharmaceutical companies to explore new therapeutic areas and develop cutting-edge treatments. These collaborations not only enhance GSK's product pipeline but also strengthen its position as a leader in global health care.

Current Market Status

As of 2023, GSK continues to maintain its status as one of the world's largest healthcare companies, with a strong presence in over 100 countries. Despite facing challenges such as patent expiries and competitive pressures, GSK has shown resilience through strategic innovations, expansions into emerging markets, and a focus on high-growth segments. The company's commitment to improving global health outcomes and investing in future growth drivers signals a positive outlook for its market position moving forward.